Pharmaceuticals, Biotechnology and Life Sciences
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics have announced that the European Commission has granted marketing authorization to Kapruvia (difelikefalin) for the treatment of moderate-to-severe pruritus associated with...
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment...
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating 20th anniversary of FDA's approval of Botox Cosmetic.
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a joint work plan until 2023....
Sanofi has launched its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors....
First known bovine model used to demonstrate safety and efficacy in gene replacement therapy MSUD is a severe genetic disease…
Natural killer (NK) cells engineered with chimeric antigen receptor (CAR) cells to better fight COVID-19 LOS ANGELES–(BUSINESS WIRE)–City of Hope…
DUBLIN–(BUSINESS WIRE)–The “Global Dermatological Drug Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. The…
Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new…
DUBLIN–(BUSINESS WIRE)–The “Anxiety Drugs Market Research Report by Type (Generic Drugs and Patent Medicine), Application, State – United States Forecast…
DUBLIN–(BUSINESS WIRE)–The “United States Spatial Genomics and Transcriptomics Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027” report…
Opportunistic proposal from activist shareholder substantially undervalues Zymeworks and is not in the best interests of shareholders Shareholders are right…
SAN DIEGO & VANCOUVER, British Columbia–(BUSINESS WIRE)–Tentarix Biotherapeutics LP, a biotechnology company developing first-in-class targeted, conditional antibody-based multifunctional biotherapies, today…
Heart Failure 2022 Presentation Includes Preclinical Data Supporting TN-301 Effect in HFpEF Models TN-301 IND Submission on Track for Second…
Opinion granted based on positive results from the Phase 3 KEYNOTE-716 trial If approved, KEYTRUDA would be the first anti-PD-1…
